The Cochrane database of systematic reviews

Using text messages to help people take heart disease prevention medicines

Updated

Abstract

A total of 8136 participants with cardiovascular diseases were included in the analysis.

  • Mobile phone text messaging may have uncertain effects on medication adherence, with 10 out of 18 studies showing a beneficial effect and 8 showing no difference or a reduction.
  • Text messaging is associated with little to no effect on fatal cardiovascular events, with an odds ratio of 0.83 based on low-certainty evidence.
  • Very low-certainty evidence suggests that text messaging may have little to no impact on non-fatal cardiovascular events and combined cardiovascular events.
  • There is also very low-certainty evidence indicating text messaging may not significantly affect low-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, or heart rate compared to usual care.
  • All included studies had a high risk of bias, and no research evaluated the effects of text messaging in low-income countries or beyond a 12-month follow-up.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

JR holds a National Health and Medical Research Council (NHMRC) Fellowship (investigator‐initiated), which supports part of her salary that includes academic time spent working on this review; and an NHMRC Synergy Grant, paid to institution. JR was one of the authors of Chow 2015 and Chow 2022. JR was not involved in assessing the eligibility of the studies, extracting data, or assessing risk of bias or the certainty of the evidence for this review update. These tasks were performed by two independent review authors (QT, NH). Chow 2015 was supported by grants from the National Heart Foundation of Australia Grant‐in‐Aid (G10S5110) and a BUPA Foundation Grant. Chow 2022 was supported by the NHMRC (APP1042290). JR retained complete control over the design, methods, data analysis, and reporting of both studies. JR did not receive the funds personally for either study and did not benefit financially from the payment or have access to or control of the funds. JR reports a trademark for the TEXTCARE software that delivers text message programmes for research, which is owned by the University of Sydney. It is not patented and was not used to deliver any of the research projects for this Cochrane review. JR has not benefitted financially from the trademark, and the University of Sydney does not intend to commercialise it. QT: none known. KH reports a grant from the National Health and Medical Research Council, which is a government‐funded fellowship and is not related to the topic. KH retains complete control over all study designs, methods, data analysis, and reporting related to her grant. MH: none known. NH: none known. CZ: none known. CF is a former editor of Cochrane Heart but was not an editor of Cochrane Heart in the 36 months prior to this review update. CF was not involved in the editorial process for this review. CF was also involved in a study eligible for inclusion in the review (Bermon 2021). The study was supported by the Ministerio de Ciencia Tecnología e Innovación (code: 656672553352; grants 899‐2015 and 753 de 2016); Fundación Cardiovascular de Colombia, Floridablanca; UK Medical Research Council Funded Reference (reference number: MR/N021304/1); and the Universidad Pontificia Bolivariana, Bucaramanga. However, CF was not involved in assessing the eligibility of the study, extracting data, or assessing risk of bias or the certainty of the evidence for this review update; these tasks were performed by two independent review authors (QT, NH). CF’s institution did not receive any payments for this study, and CF had complete control over the study design, methods, data analysis, and reporting. PP has published an opinion on the topic of text messaging, Adler 2018, and several editorials, but these were unrelated to the current review. PP is affiliated with the World Heart Federation, and was and remains affiliated to London School of Hygiene & Tropical Medicine, but the organisation received no financial contribution for PP's work on this Cochrane review and had no involvement in the protocol or published work. PP is a former editorial advisor of the Cochrane Heart Group and was not involved in the editorial process for this review update. PP was also involved in the Bermon 2021 study, which was eligible for inclusion in the review. The study was supported by the Ministerio de Ciencia Tecnología e Innovación (code: 656672553352; grants 899‐2015 and 753 de 2016); Fundación Cardiovascular de Colombia, Floridablanca; and UK Medical Research Council Funded Reference (reference number: MR/N021304/1). However, PP was not involved in assessing the eligibility of the study, extracting data, or assessing risk of bias or the certainty of the evidence for this review update; these tasks were performed by two independent review authors (QT, NH). PP’s institution did not receive any payments for this study, and PP had complete control over the study design, methods, data analysis, and reporting. CKC was one of the authors of Chow 2015 and Chow 2022. CKC was not involved in assessing the eligibility of the studies, extracting data, or assessing risk of bias or the certainty of the evidence for this review update. These tasks were performed by two independent review authors (QT, NH). Chow 2015 was supported by grants from the National Heart Foundation of Australia Grant‐in‐Aid (G10S5110) and a BUPA Foundation Grant. Chow 2022 was supported by the National Health and Medical Research Council (NHMRC) (APP1042290). CKC was the Principal Investigator for both of these studies, and, as such, payments were made to her institution, University of Sydney, for delivery of the research projects (such as paying research assistants and to perform measurements and analyses). However, both studies were investigator‐initiated, and CKC received no direct financial gain and retained complete control over the study design, methods, data analysis, and reporting. CKC holds an NHMRC Fellowship (investigator‐initiated), which supports part of her salary that includes academic time spent working on this review; paid to institution, but CKC benefitted or had control over the funds. CKC is a Cardiologist at Westmead Hospital in Australia. CKC reports a trademark for the TEXTCARE software that delivers text message programmes for research, which is owned by the University of Sydney. It is not patented and was not used to deliver any of the research projects for this Cochrane review. CKC has not benefitted financially from the trademark, and the University of Sydney does not intend to commercialise it. CKC has also published an opinion piece on the topic of text messaging (Klimis 2021).
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free